// Precision Drug Delivery · Microneedles & Implants
Bring us your molecule — we transform it into a patient-friendly patch. BIOAXXENT engineers dissolving microneedle arrays and polymeric implants that make treatment painless, stress-free and self-manageable at home
A novel microneedle delivery concept built on know-how developed entirely in-house — and a process lean enough to move from molecule to prototype in weeks, not quarters. That combination is hard to replicate and hard to catch up to.
Each array contains dozens of micro-sharp tips, engineered with sub-micron accuracy for consistent transdermal delivery.
Customized polymer matrices encapsulate the active molecule — releasing it in a controlled, reproducible manner upon skin contact
Making effective therapies more accessible — through innovation that puts the patient first.
For large pharma, the opportunity isn't just replacing a needle — it's extending the commercial utility of a molecule through a more convenient, scalable and differentiated delivery format.
A new delivery presentation can defend and refresh a mature brand's franchise value ahead of or after loss of exclusivity.
Minimally invasive, patch-like dosing can reduce needle burden and improve adherence, persistence and patient preference.
The strongest companies monetize through co-development, licensing, milestones and royalties across multiple molecules — not a single asset.
Biologics, vaccines and decentralized care are emerging use cases where dermal delivery can outperform oral or injectable formats — and where thermostability and reduced sharps waste improve cost-to-serve.
Molecular formulation at the tip of a needle.
Our microneedle arrays and polymeric implants are fabricated with sub-micron precision, embedding active pharmaceutical ingredients directly within a biocompatible polymer matrix. Each device is architected to dissolve or release at a controlled rate — governed by molecular interactions between drug, excipient, and tissue
Most partners hand you a case study. We show you our modeling in action. Adjust needle height, protein concentration, and penetration depth, and watch delivered dose calculate in real time. This simplified demo is just a glimpse — the real computational precision behind every BIOAXXENT formulation runs far deeper, applied weeks before a single prototype is built.
This is a simplified public preview. Our full configurator models your specific molecule — its solubility, stability, and required dose — against real skin-permeation data, and outputs a manufacturable design ready for prototyping.
BIOAXXENT's proprietary formulation approach maps the multi-dimensional interaction space between active molecules, excipients, and biological membranes — accelerating formulation design from months to days.
Our advanced molecular screening computes free energies of binding, diffusion coefficients, and phase stability across thousands of candidate formulations simultaneously — reducing experimental waste by over 70%.
Making effective therapies more accessible, through innovation that puts the patient first.
Polymeric Implant
Sub-mm Scale
A single dissolving microneedle array, framed by the very injections it is designed to replace.
Roughly 16 billion injections are administered worldwide every year, and not all of the resulting sharps are disposed of safely. A dissolving microneedle array removes the steel needle, the glass vial and, in many formulations, the refrigerated supply chain that carries them. The environmental case here is structural rather than incidental.
Dissolving polymer microneedles disappear into the skin after application, so no contaminated steel enters the waste stream. Conventional injection generates hazardous sharps waste that has to be segregated, boxed and incinerated. At low temperatures or in open burning, that final step can release dioxins, furans and particulate matter. WHO, Health-care waste fact sheet, 2024
A dry, solid-state patch avoids the aqueous formulation that makes most injectables heat-sensitive. Dissolving polymer microneedle patches have retained vaccine activity for up to 24 months at 25 °C, displacing the energy demand, refrigerant leakage and last-mile infrastructure that a continuous 2 to 8 °C chain requires. Mistilis et al., Drug Deliv Transl Res 7(2):195–205, 2017; Moon et al., Hum Vaccin Immunother 21:2555700, 2025
The WHO has estimated that up to half of all vaccine doses are wasted globally each year, much of it through temperature excursions and part-used multi-dose vials. A thermostable single-dose patch removes both failure modes, and with them the full manufacturing footprint embodied in every discarded dose. WHO estimate, reported by UNEP and the World Economic Forum; Prausnitz et al., Curr Opin Virol 41:68–76, 2020
A standard injection arrives as a multi-component kit: glass vial, syringe barrel, needle, alcohol wipe, sharps container, insulated shipper and secondary packaging. A patch consolidates all of that into a single dry format of roughly one cubic centimetre, cutting packaging mass and shipping volume across the entire chain. Arya & Prausnitz, J Control Release 240:135–141, 2016
In a liquid formulation, water gives protein molecules the freedom to move, and above a certain temperature they unfold irreversibly. Drying the same molecule into a sugar-glass microneedle matrix removes that freedom. The protein is held in a rigid amorphous solid, so heat has far less structure left to disrupt. Drag to rotate, or move the slider.
Schematic representation of the vitrification mechanism, not measured data. For a published
comparison: after one month at 42 °C a dissolving microneedle array patch carrying a protein
subunit vaccine showed under 3 % protein degradation, against over 23 % for the same antigen
in liquid form.
Kim et al., Vaccines 13(1):86, 2025 (murine study; degradation by densitometry)
BIOAXXENT collaborates with leading academic institutions and innovation labs to advance microneedle science and formulation technology.
01
Thomas is a pharmaceutical technology leader with deep expertise in advanced drug delivery and polymer science. He is the author of approximately 25 peer-reviewed publications on innovative drug delivery technologies and 3D-printed dosage forms, developed in collaboration with leading academic groups. With prior roles at Sanofi, Glatt, and Merck KGaA, he brings over 15 years of experience in R&D, drug development, process scale-up, and strategic technology implementation.
02
Iris is a senior Corporate Development and M&A executive with over 25 years of experience in the pharma and healthcare industry. Most recently Executive Director at Merz Therapeutics, she led global licensing, partnerships, M&A, and venture investments in neurology — executing transactions from early-stage biotech to commercial-asset acquisitions. With board-level roles and a strong background in strategy, R&D, and innovation, she brings a proven track record across Merz, Novartis, and Merck.
03
Stefan is a biotech and healthcare entrepreneur with over 30 years of leadership experience in pharma, drug delivery, and pharmacy operations. He is CEO of BIOAXXENT and runs a network of innovative pharmacies. A named inventor on multiple microneedle and drug delivery patents, he previously held senior R&D and executive roles at Schering AG, Boehringer Ingelheim, Merck, and Merz, with deep expertise in transdermal delivery, needle-free injection systems, and patient-centered solutions.
We collaborate with pharmaceutical companies, biotech startups and academic institutions to develop breakthrough microneedle delivery systems — from initial feasibility to clinical-stage formulation
Nobody chooses to be sick. Nobody should fear their treatment. At BIOAXXENT, we believe that the science of drug delivery has a human obligation — to make medicine more accessible, more comfortable, and more effective for every patient
1 in 4 adults experiences needle anxiety. For patients managing chronic conditions — diabetes, hormone therapy, immunology — requiring regular injections, this creates a real and measurable barrier to treatment compliance. BIOAXXENT's dissolving microneedle arrays make administration painless, stress-free and self-manageable at home — removing fear from the equation entirely
Many therapeutic peptides, proteins and biologics are destroyed by stomach acid before they ever reach the bloodstream. Transdermal delivery through the skin bypasses this entirely — opening a new class of molecules to non-injectable, patient-friendly administration. What previously required a clinic visit and a syringe can now be applied in seconds at home
Through advanced polymer formulation and molecular screening, BIOAXXENT engineers each microneedle array specifically for the molecule it carries — optimising release kinetics, stability and skin permeation. The result is a delivery system that is gentler, simpler and more accessible — turning complex pharmaceutical science into a seamless patient experience
"We formulate for the molecule.
We design for the patient."
BIOAXXENT GmbH
We look forward to hearing from you. Send us a message and we will get back to you shortly.
Thank you! Your message has been sent.
We will be in touch soon.
BIOAXXENT GmbH
Bahnhofstr. 18–20
57518 Betzdorf
Germany
Contact
Phone: +49 175 5225532
E-Mail: info@bioaxxent.com
Web: www.bioaxxent.com
Geschäftsführer
Dr. Stefan Henke
Handelsregister
Amtsgericht Montabaur, HRB 30638
Rechtsform: Gesellschaft mit beschränkter Haftung
Umsatzsteuer
Umsatzsteuer-ID: 02/660/15938
1. General Information
Protecting your personal data is important to us. This website is intended solely to provide information about our company, our technology platform, and our research and development activities.
We process personal data exclusively in accordance with applicable data protection laws, in particular the General Data Protection Regulation (GDPR).
2. Data Controller
Bioaxxent GmbH
Bahnhofstr. 18–20
57518 Betzdorf
Deutschland
E-Mail: info@bioaxxent.com
A data protection officer has not been appointed, as the legal requirements are not met.
3. Website Access
When visiting our website, certain technical information is automatically collected by the hosting provider, including:
This data is processed to ensure the technical functionality, stability, and security of the website.
The legal basis for this processing is Art. 6(1)(f) GDPR.
4. Contact Requests and Business Inquiries
If you contact us via email or contact form, we process the information you provide (such as your name, company, position, contact details, and the content of your inquiry) in order to respond to your request.
This applies in particular to:
Processing is carried out either:
Your data will be used solely for handling your inquiry and maintaining related business communications.
5. Data Sharing
Personal data may be shared with technical service providers (such as hosting providers) where necessary for operating the website.
No further disclosure of personal data will take place without your explicit consent unless required by law.
6. Data Retention
We retain personal data only as long as necessary to process your inquiry, maintain business relationships, or comply with legal retention obligations.
7. Your Rights
Under applicable law, you have the right to:
You also have the right to lodge a complaint with a competent data protection supervisory authority.
8. Data Security
We implement appropriate technical and organizational measures to protect your data against loss, misuse, or unauthorized access.
9. Changes to this Privacy Policy
We reserve the right to amend this Privacy Policy as necessary, particularly in the event of changes to our website or legal requirements.
Last updated: May 2026